Product Pipeline

Our platform

Our unique PDSP technology platform accelerates drug development.

BRIM accelerates drug development from preclinical to clinical proof of concept, targeting novel therapies for diseases with high unmet medical needs. Our projects are based on our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform, which can be applied across multiple therapy areas and indications.

Novel therapies

Novel therapies for diseases with high unmet medical needs.

Our lead asset, BRM421, is on track to become a first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage. BRM421 is currently in Phase II/III clinical trials. We are also developing new drugs to treat severe corneal damage (BRM423) and osteoarthritis (BRM521), both of which are developed from our PDSP technology platform.

PRE-CLINICAL Phase 1 Phase 2 Phase 3 Dry Eye Syndrome MOA: Regeneration BRM 421 Severe Cornea Damage MOA: Regeneration BRM 423 Neurotrophic Keratitis(NK) MOA: Regeneration BRM 424 Osteoarthritis MOA: Regeneration BRM 521

Dry Eye Syndrome

A potential first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage.

Severe Cornea Damage

Targeted to treat severe cornea damage which can lead to blindness.

Neurotrophic Keratitis (NK)

Early-stage treatment in development for Neurotrophic Keratitis (NK), a rare, degenerative disease affecting the cornea.

Osteoarthritis

Unique mechanism of action promotes joint cartilage regeneration and relieves pain caused by osteoarthritis.

"The integrity of BRIM is something that makes it stand out in this sector."

"The entire supply chain, the entire CMC issue, everything is so much more straightforward for the peptide approach compared to stem cell therapy"

"That's the most exciting part of this project - that we've found a peptide with the function of a much larger protein."